Polpharma Biologics announces a global (except for Middle East & North Africa) licensing agreement with Fresenius Kabi for the commercialisation of PB016, a proposed biosimilar to vedolizumab, an integrin receptor antagonist, a biologic therapy indicated...
Read More
1 Minute
